Merck presents innovative containment project at Pharma Congress

Heidelberg - 28.3.2019

At this year’s Pharma Congress in Düsseldorf, consulting and planning company io-consultants presents innovative single use, continuous manufacturing, and containment solutions that will set the standard for the future. By focussing on new technologies, the biotech and pharma experts go that extra mile to offer intelligent investment concepts for pharmatech projects.

The Pharma Congress, which is held for the 21st time in April this year, is one of the most prestigious conferences and exchange platforms for the pharmaceutical technology industry in Germany and continues to make a name for itself as an international forum. Under the lead theme “Users report for Users”, the conference focuses on exchanging practical experiences gained from recent state-of-the-art projects. io-consultants offers visitors valuable insights into a variety of their pharmatech projects providing a wealth of information on customized strategies and concepts while also discussing new ideas to tackle the challenges of today’s pharmatech operations.

One of the highlights of this year’s conference is the presentation by Merck’s Dr. Ralph Sapper describing the Solida Pilot Plant for highly potent active ingredients, which was planned and implemented in partnership with io-consultants as their lead consultant.

The GMP-compliant Solida Pilot Plant comprises a pharmaceutical solids manufacturing facility with OEB 5 containment, which is being constructed within the already densely equipped existing facilities. Due to this limited production and technology space, all disciplines involved needed to be carefully planned and coordinated using an integrated 3D model. The Solida Pilot Plant is due to be completed very soon and Merck is already planning the implementation of a GMP-compliant pilot plant for injectables – once again working with io-consultants as their lead consultant.

Downloads

Please contact us

Nathalie Müller Marketing & Public Relations Phone: +49 (0) 62 21 / 379-241